Bracco LumenHance GI imaging agent pediatric supplement to be filed within six months of Dec. 19 approval.
BRACCO LUMENHANCE PEDIATRIC SUPPLEMENT WILL BE FILED WITHIN SIX MONTHS of the contrast agent's Dec. 19 approval, the company and FDA agreed. The supplement will contain pediatric dosing recommendations based on oral volume information contained in medical references and literature. One issue the company will evaluate is whether to decrease the adult dose or to dose according to body mass. Bracco noted that after LumenHance (manganese chloride) is launched, the company plans to create an open registry of pediatric patients.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth